Royal Bank of Canada
ACXP icon

Royal Bank of Canada’s Acurx Pharmaceuticals ACXP Stock Holding History

Royal Bank of Canada’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7
Closed – – 6785
2024
Q2 		$0 Buy
7
+5
+250% +$220 ﹤0.01% 6974
2024
Q1 		$0 Sell
2
-1
-33% -$65 ﹤0.01% 6943
2023
Q4 		$0 Buy
3
+1
+50% +$75 ﹤0.01% 7052
2023
Q3 		$0 Sell
2
-4
-67% -$153 ﹤0.01% 7023
2023
Q2 		$0 Buy
+6
New +$357 ﹤0.01% 7194
2022
Q4 		– Sell
-4
Closed – – 7165
2022
Q3 		$0 Buy
+4
New +$299 ﹤0.01% 7393

Other funds holding ACXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Royal Bank of Canada's ACXP Position: Q3 2024 in Review

Royal Bank of Canada sold out of Acurx Pharmaceuticals (ACXP) in Q3 2024, closing a stake of 7 shares.

Royal Bank of Canada first reported a position in ACXP in Q3 2022 and held it in 6 quarters. The position peaked at $0 in Q2 2024. 22 funds tracked by Wall St. Rank hold ACXP as of Q3 2024.

  • Royal Bank of Canada reported no remaining Acurx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 7 Acurx Pharmaceuticals shares in Q3 2024.
  • Royal Bank of Canada first reported a position in Acurx Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Royal Bank of Canada's Acurx Pharmaceuticals position peaked at $0 in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.